Full Thickness Macular Hole; Should it be Handled Subacutely?

Recruiting N/A Interventional Study
Full Thickness Macular Hole
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
56 (estimated)
Sponsor
Rigshospitalet, Denmark · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Full thickness macular hole, FTMH, is a retinal disease involving the fovea that cause central vision loss, metamorphopsia and central scotoma. The most effective treatment for FTMH is a pars plana vitrectomy and a tamponade with expansile gas. It is well known that vitrectomy accelerates cataract development. Vitrectomy can therefore be combined with cataract surgery in the same setting, a proced…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Idiopathic full thickness macular hole * Duration of symptoms of \<30 days for Group 1 and 2 * Duration of symptoms of 3-12 months for Group 3 * FTMH size \<400µm * \>18 years * Able to give informed consent * Compliance for postoperative positioning Exclusion Criteria: * Hi…
Contacts

Asrin Rasul, MD

004522365420

asrin.rasul@regionh.dk

CONTACT

Ulrik Christensen

004540261670

ulrik.correll.christensen@regionh.dk

CONTACT